Synapse - Works

Results (2950)

Continuous treatment with lenalidomide plus low-dose dexamethasone (Ld) versus Ld induction followed by autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (NDMM): A pooled analysis of two randomized clinical trials

Meeting Abstract

Lentzsch, S.; Villanueva, N.; Nguyen, J.; Landau, H.; Lendvai, N.; Miao, S.; Schecter, J. M.; Reyna, M.; Mapara, M. Y.; Redner, R. L.; more...
Blood (2015)

Fulltext@MSK | Save

No risk of arterial or venous thrombosis in monoclonal gammopathy of undetermined significance: Results from a population-based study

Meeting Abstract

Lindqvist, E. K.; Lund, S. H.; Costello, R.; Burton, D.; Korde, N. S.; Mailankody, S.; Gudnason, V.; Eiriksdottir, G.; Launer, L.; Harris, T. B.; more...
Blood (2015)

Fulltext@MSK | Save

Biomarkers of cardiotoxicity among multiple myeloma patients subsequently treated with proteasome inhibitor therapy

Meeting Abstract

Lendvai, N.; Devlin, S.; Patel, M.; Knapp, K. M.; Ekman, D.; Grundberg, I.; Chung, D. J.; Hassoun, H.; Koehne, G.; Lesokhin, A. M.; more...
Blood (2015)

Fulltext@MSK | Save

Investigating effect of genetic admixture and donor/recipient genetic disparity on transplant outcomes

Meeting Abstract

Madbouly, A.; Wang, T.; Albrecht, M.; Paunic, V.; Haagenson, M. D.; Vierra-Green, C.; Fleischhauer, K.; Hsu, K. C.; Verneris, M. R.; Majhail, N. S.; more...
Blood (2015)

Fulltext@MSK | Save

Induction with bortezomib and dexamethasone (BD) followed by risk adapted high dose melphalan and autologous stem cell transplantation and BD consolidation in patients with AL amyloidosis: A phase II feasibility study

Meeting Abstract

Landau, H.; Montanez, N.; Cowan, A.; Hoover, E.; Flombaum, C.; Liu, J.; Maurer, M.; Lendvai, N.; Landgren, O.; Giralt, S. A.; more...
Blood (2015)

Fulltext@MSK | Save

High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse risk features and poor outcome in pediatric acute myeloid leukemia: A report from the Children's Oncology Group

Meeting Abstract

Laszlo, G. S.; Alonzo, T. A.; Gudgeon, C. J.; Harrington, K. H.; Kentsis, A.; Gerbing, R. B.; Wang, Y. C.; Ries, R. E.; Raimondi, S. C.; Hirsch, B. A.; more...
Blood (2015)

Fulltext@MSK | Save

Incidence and management of proteasome inhibitor-related cardiotoxicity in multiple myeloma patients at Memorial Sloan Kettering Cancer Center

Meeting Abstract

Land, J.; Afifi, S.; Adel, N. G.; Devlin, S.; Arora, A.; Lendvai, N.; Landgren, O.
Blood (2015)

Fulltext@MSK | Save

Phase 1 trial of targeted alpha-particle immunotherapy with actinium-225 ((225)Ac)-lintuzumab (Anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML)

Meeting Abstract

Jurcic, J. G.; Ravandi, F.; Pagel, J. M.; Park, J. H.; Smith, B. D.; Levy, M. Y.; Estey, E. H.; Perl, A. E.; Kantarjian, H.; Earle, D.; more...
Blood (2015)

Fulltext@MSK | Save

An HSP90 inhibitor, PU-H71, antagonizes stroma-induced pro-survival effects in CLL through its inhibition of multi-component B-cell receptor signaling pathway

Meeting Abstract

Guo, A. L.; Lu, P.; Zhen, C.; Chiosis, G.; Wang, Y. L.
Blood (2015)

Fulltext@MSK | Save

The long PD-1 receptor binding kinetics of nivolumab may increase efficacy of subsequent therapy in relapsed and refractory multiple myeloma patients

Meeting Abstract

Funt, S. A.; Page, D. B.; Cattry, D.; Lendvai, N.; Hassoun, H.; Landgren, O.; Borrello, I. M.; Lesokhin, A. M.
Blood (2015)

Fulltext@MSK | Save